23-Hydroxybetulinic Acid, A Natural Compound, Alleviates DSS-induced Colitis by Regulating NF-κB Signaling

Shuangli Xiang; Miaojuan Wang; Xiuping Chen

doi:10.53941/ijddp.0201007

Abstract

Ulcerative colitis (UC), an inflammatory intestinal disease, is a growing epidemic affecting people worldwide and requires the development of effective therapeutic drugs. In this study, the effect of 23-hydroxybetulinic acid (23-HBA), a compound isolated from the traditional herb Pulsatilla chinensis (Bunge) Regel, on experimental UC was studied. C57BL/6J male mice were administrated with 3% dextran sodium sulfate (DSS) in drinking water to establish the UC model. 23-HBA was orally administrated at either 3.75, 7.5, or 15 mg/kg for 6 days. Mesalazine was used as a positive control. Examination of the body weight, colon length, disease activity index (DAI), histopathology examination, inflammatory cytokines, oxidative stress, and protein expression was performed. The pathological changes were examined with hematoxylin and eosin (H&E) and Aixian blue-glycogen (AB-PAS) staining. In cultured RAW 264.7 cells, the effects of 23-HBA on lipopolysaccharide (LPS)-stimulated cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and oxidative stress were analyzed. Compared with the colitis model, 23-HBA treatment significantly increased the body weight and colon length and decreased the DAI score. Pathological staining showed that 23-HBA mitigated the damage in intestinal structures, the increase in inflammatory cell infiltration, the increase in submucosa edema, and the decrease in goblet cell number. Furthermore, 23-HBA decreased IL-1β, IL-6, and MDA levels in the colon tissues. In addition, 23-HBA inhibited the protein expressions of COX-2, iNOS, and NF-κB p65 both in the colon tissues and in LPS-stimulated RAW 264.7 cells. In conclusion, these results showed that 23-HBA alleviated DSS-induced acute UC in mice and inhibited LPS-stimulated inflammation in RAW 264.7 cells possibly mediated by regulating the NF-κB pathway.

References

1.
Ungaro R.; Mehandru S.; Allen P.B.; et al. Ulcerative colitis. The Lancet, 2017, 389(10080): 1756-1770.
2.
Ng S.C.; Tang W.; Ching J.Y.; et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology, 2013, 145(1): 158-165 e152.
3.
Park J.A.-O.;Cheon J.A.-O. Incidence and Prevalence of Inflammatory Bowel Disease across Asia. Yonsei Med. J. 2021, 62(2): 99-108.
4.
Hendrickson B.A.; Gokhale R.;Cho J.H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev., 2002, 15(1): 79-94.
5.
Ordás I.; Eckmann L.; Talamini M.; et al. Ulcerative colitis. The Lancet, 2012, 380(9853): 1606-1619.
6.
Zhou J.; Lai W.; Yang W.; et al. BLT1 in dendritic cells promotes Th1/Th17 differentiation and its deficiency ameliorates TNBS-induced colitis. Cell. Mol. Immunol., 2018, 15(12): 1047-1056.
7.
Miao Z.; Chen L.; Feng H.; et al. Baitouweng Decoction Ameliorates Ulcerative Colitis in Mice Partially Attributed to Regulating Th17/Treg Balance and Restoring Intestinal Epithelial Barrier. Front. Pharmacol., 2020, 11: 531117.
8.
Chen X.-Q.; LV X.-Y. ; Liu S.-J. Baitouweng decoction alleviates dextran sulfate sodium-induced ulcerative colitis by regulating intestinal microbiota and the IL-6/STAT3 signaling pathway. J. Ethnopharmacol., 2021, 265: 113357.
9.
Wang X.; Xu L.; Wang T.; et al. Pulsatilla decoction alleviates colitis by enhancing autophagy and regulating PI3KAktmTORC1 signaling pathway. Mol. Med. Rep., 2022, 25(3).
10.
Li Y.H.; Zou M.; Han Q.; et al. Therapeutic potential of triterpenoid saponin anemoside B4 from Pulsatilla chinensis. Pharmacol. Res., 2020, 160: 105079.
11.
Ye B.;Ji Z.N. 23-hydroxybetulinic acid-induced HL-60 cell autophagic apoptosis and its molecular mechanism. Nat. Prod. Res., 2012, 26(11): 1063-1068.
12.
Ji Z.N.; Ye W.C.; Liu G.G.; et al. 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL-60 Cells. Life Sci., 2002, 72(1): 1-9.
13.
Zhou F.; Hao G.; Zhang J.; et al. Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism. Br. J. Pharmacol., 2015, 172(23): 5690-5703.
14.
Ma H.; Zhou M.; Duan W.; et al. Anemoside B4 prevents acute ulcerative colitis through inhibiting of TLR4/NF-κB/MAPK signaling pathway. Int. Immunopharmacol., 2020, 87: 106794.
15.
Wirtz S.; Popp V.; Kindermann M.; et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat. Protoc., 2017, 12(7): 1295-1309.
16.
Zhou Y.; Zhong B.; Min X.; et al. Therapeutic potential of isobavachalcone, a natural flavonoid, in murine experimental colitis by inhibiting NF-κB p65. Phytother. Res., 2021, 35(10): 5861-5870.
17.
Wu X.; Guo Y.; Min X.; et al. Neferine, a Bisbenzylisoquinoline Alkaloid, Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis. Am. J. Chin. Med., 2018, 46(6): 1263-1279.
18.
Guo Y.; Wu X.; Wu Q.; et al. Dihydrotanshinone I, a natural product, ameliorates DSS-induced experimental ulcerative colitis in mice. Toxicol. Appl. Pharmacol., 2018, 344: 35-45.
19.
Eichele D.D.;Kharbanda K.K. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J. Gastroenterol., 2017, 23(33): 6016-6029.
20.
Perše M.;Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J. Biomed. Biotechnol., 2012, 2012: 718617.
21.
Chen L.; Teng H.; Fang T.; et al. Agrimonolide from Agrimonia pilosa suppresses inflammatory responses through down-regulation of COX-2/iNOS and inactivation of NF-kappaB in lipopolysaccharide-stimulated macrophages. Phytomedicine, 2016, 23(8): 846-855.
22.
Lee J.S.; Kim H.S.; Hahm K.B.; et al. Effects of Genetic and Pharmacologic Inhibition of COX-2 on Colitis-associated Carcinogenesis in Mice. J. Cancer Prev., 2020, 25(1): 27-37.
23.
Kotha Subbaramaiah N.T., John T. Ramonetti, Ruriko Araki, Bethany De Vito, Babette B. Weksler, and Andrew J. Dannenberg. Transcription of Cyclooxygenase-2 Is Enhanced in Transformed Mammary Epithelial Cells. Cancer Res., 1996, 56(19): 4424-4429.
24.
Middleton S.J.; Shorthouse M.;Hunter J.O. Increased nitric oxide synthesis in ulcerative colitis. The Lancet, 1993, 341(8843): 465-466.
25.
Yuan R.; He J.; Huang L.; et al. Anemoside B4 Protects against Acute Lung Injury by Attenuating Inflammation through Blocking NLRP3 Inflammasome Activation and TLR4 Dimerization. J. Immunol. Res., 2020, 2020: 7502301.
26.
Kaur A.;Goggolidou P. Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies. J. Inflamm. (Lond), 2020, 17: 15.
27.
Nakase H.; Sato N.; Mizuno N.; et al. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun. Rev., 2022, 21(3): 103017.
28.
Pereira C.; Grácio D.; Teixeira J.P.; et al. Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease. Inflamm. Bowel. Dis., 2015, 21(10): 2403-2417.
29.
Atreya I.; Atreya R.;Neurath M.F. NF-kappaB in inflammatory bowel disease. J Intern Med., 2008, 263(6): 591-596.
30.
DiDonato J.A.; Mercurio F.;Karin M. NF-κB and the link between inflammation and cancer. Immunol. Rev., 2012, 246(1): 379-400.
31.
Surh Y.J.; Chun K.S.; Cha H.H.; et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res., 2001, 480-481: 243-268.
32.
Giridharan S.;Srinivasan M. Mechanisms of NF-κB p65 and strategies for therapeutic manipulation. J. Inflamm. Res., 2018, 11: 407-419.
33.
Zhou Y.; Xiang S.; Zheng H.; et al. Neferine Suppresses Experimental Colitis-Associated Colorectal Cancer by Inhibition of NF-[Formula: see text]B p65 and STAT3. Am. J. Chin. Med., 2022, 50(5): 1387-1400.
34.
Nam N.H. Naturally occurring NF-kappaB inhibitors. Mini. Rev. Med. Chem., 2006, 6(8): 945-951.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us